Clinical features | N(%) |
---|---|
Gender | |
Male | 17(53) |
Female | 15(47) |
Age | |
< 60 | 18(56) |
≥ 60 | 14(44) |
Type of pathology | |
Metastatic adenocarcinoma | 15(47) |
Metastatic squamous carcinoma | 8(25) |
Neuroendocrine carcinoma | 5(16) |
Metastatic undifferentiated carcinoma | 4(12) |
Treatment options | |
Treatment options with good prognosis | 7(22) |
Treatment options with poor prognosis | 19(59) |
NGS(next generation sequencing)-guided treatment | 6(19) |
Diagnostic site | |
Superficial lymph node puncture | 16(50) |
Involved organ biopsy | 9(28) |
Malignant cells found in thoraco-peritoneal fluid | 7(22) |
Involved organs | |
< 3 | 20(63) |
≥ 3 | 12(37) |
Adverse effects(grade III-IV) after treatment | |
Yes | 18(56) |
No | 14(44) |